linagliptin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 31 Diseases   34 Trials   34 Trials   1690 News 


«12...4567891011121314...1819»
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Trial completion date, Trial primary completion date:  Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus. (clinicaltrials.gov) -  Feb 24, 2021   
    P3,  N=660, Not yet recruiting, 
    Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Gemiglo (gemigliptin) / Sanofi, LG Chem
    Journal:  Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection. (Pubmed Central) -  Jan 13, 2021   
    These computational studies led to the identification of three marketed DPP4 inhibitors; gemigliptin, linagliptin and evogliptin as potential inhibitors of SARS-CoV-2 M viral cysteine protease. In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV M and MERS-CoV CL suggesting their potential to be repurposed as broad-spectrum antiviral agents.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Trial initiation date, Trial primary completion date:  Effects of DPP4 Inhibition on COVID-19 (clinicaltrials.gov) -  Jan 11, 2021   
    P4,  N=20, Not yet recruiting, 
    In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV M and MERS-CoV CL suggesting their potential to be repurposed as broad-spectrum antiviral agents. Initiation date: Jan 2021 --> Jun 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
    [VIRTUAL] Liraglutide and robust A1c reductions in patients requiring appetite control: a review of two cases () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_3384;    
    A clinical pharmacist had managed his A1c down from 12.8 percent to 8.8 percent with sitagliptin 100mg daily, and large doses of insulin up to glargine U-100 80 units twice daily and aspart 50 units with meals; he had not tolerated metformin...Upon referral to the clinical pharmacist, his baseline A1c of 13.6 percent was managed with linagliptin 5mg daily and insulin degludec U-100 40 units daily; he had not tolerated metformin...When appetite control is a major barrier to overall control of A1c, the GLP-1 RA liraglutide may help patients to significantly reduce food intake to appropriate levels, resulting in impressive and unexpected reductions in A1c beyond the anticipated 1 percent; in these cases, 3.0 to 6.5 percent reductions from initiation of liraglutide. This may remove or greatly reduce the need for insulin treatment and adverse effects of hypoglycemia and weight gain.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jentadueto (linagliptin/metformin) / Eli Lilly, Boehringer Ingelheim
    In #CDMX, Trayenta Duo is out... (Twitter) -  Dec 25, 2020   
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis. (Pubmed Central) -  Dec 19, 2020   
    In transmission electron microscopy, platelets pretreated with linagliptin showed markedly reversed morphological changes in thrombin-activated platelets, including the secretion of α-granules and fewer mitochondria. Collectively, these findings identify distinct roles for DPP-4 in platelet function and arterial thrombosis.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT. (Pubmed Central) -  Dec 17, 2020   
    We have shown that the DPP-4 inhibitor linagliptin can inhibit endothelial-mesenchymal transition (EndMT) and ameliorate diabetic kidney fibrosis associated with DPP-4 protein levels via the induction of miR-29...H19, miR-29a, and EndMT contribute to a regulatory network involved in kidney fibrosis, and are associated with regulation of the TGF-β/SMAD3 singling pathway. This study indicates that inhibition of LncRNA H19 represents a novel anti-fibrotic treatment for diabetic kidney diseases.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes. (Pubmed Central) -  Dec 17, 2020   
    In summary, linagliptin offers protection against DKD by enhancing IRS1/Akt insulin signalling in podocytes and partially via the Keap1/Nrf2 pathway. Our findings suggest that linagliptin may induce protective effects in patients with DKD, and increasing IRS1 levels could be a potential therapeutic target in DKD.
  • ||||||||||  Review, Journal:  Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? (Pubmed Central) -  Dec 16, 2020   
    Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin.
  • ||||||||||  HSK7653 / Haisco
    Enrollment open:  HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Nov 22, 2020   
    P3,  N=450, Recruiting, 
    These findings have clinical implications for dermatologists and the management of patients with diabetes and being treated with DPPI agents. Not yet recruiting --> Recruiting
  • ||||||||||  linagliptin / Generic mfg.
    Trial completion, Enrollment change:  Linagliptin and Mesenchymal Stem Cells: A Pilot Study (clinicaltrials.gov) -  Nov 8, 2020   
    P4,  N=10, Completed, 
    Switching from linagliptin to teneligliptin helps maintain kidney function and reduce blood glucose safely in older patients with T2D. Recruiting --> Completed | N=18 --> 10
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Trial completion date, Trial primary completion date, Real-world evidence, Adherence, Real-world:  Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose (clinicaltrials.gov) -  Nov 4, 2020   
    P=N/A,  N=500, Recruiting, 
    Recruiting --> Completed | N=18 --> 10 Trial completion date: Jun 2021 --> Mar 2022 | Trial primary completion date: Jun 2021 --> Mar 2022
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2. (Pubmed Central) -  Nov 1, 2020   
    Linagliptin, a clinically available DPP4 inhibitor, was observed to abrogate the soluble DPP4-induced expression of fibrotic proteins...Our data extend the current view of soluble DPP4. Elevated levels of circulating soluble DPP4 may contribute to one of the mediators that induce dermal fibrosis in patients.
  • ||||||||||  [VIRTUAL] A Combined Effect of Sacubitril/Valsartan and Evolocumab on Chronic Heart Failure in an ESRD Patient () -  Oct 27, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3965;    
    His medication list included enalapril, valsartan, carvedilol, clonidine, amlodipine, hydralazine, isosorbide mononitrate, ranolazine, aspirin, warfarin, amiodarone, erythropoietin, rosuvastatin, sevelamer, linagliptin, and insulin...The combined use of sacubitril/valsartan and evolocumab in our patient for 10 months resulted in an improvement of his EF from 15% to 60%, most likely due to a significant improvement of coronary blood flow with a recovery of hibernating ischemic myocardium. Therefore, additional studies are highly recommended to explore the beneficial effect of these medications used in combination.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Glucocorticoids mobilize macrophages by transcriptionally up-regulating the exopeptidase DPP4. (Pubmed Central) -  Oct 24, 2020   
    Moreover, glucocorticoid-induced DPP4 activation was also observed in proinflammatory M1-polarized murine macrophages, as well as peritoneal macrophages, and was associated with increased macrophage migration. Our results indicate that glucocorticoids directly up-regulate DPP4 expression and thereby induce migration in macrophages, potentially explaining why glucocorticoid therapy is less effective in controlling macrophage-dominated inflammatory disorders.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  Linagliptin and bullous pemphigoid: the story continues (Pubmed Central) -  Oct 24, 2020   
    Our results indicate that glucocorticoids directly up-regulate DPP4 expression and thereby induce migration in macrophages, potentially explaining why glucocorticoid therapy is less effective in controlling macrophage-dominated inflammatory disorders. No abstract available
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Loniten (minoxidil) / Pfizer
    [VIRTUAL] Minoxidil-Induced Chylous Ascites in a Renal Transplant Recipient (On-Demand) -  Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_3215;    
    Discussion Minoxidil causes vasodilatation like calcium channel blockers though by a different mechanism so the mechanisim of chylous ascites formation could be the same that it is also a lipophilic drug allowing it to pass rapidly into the lymphatic system and causes relaxation of smooth muscles of lymphatic vessels,interferes with lymphatic drainage, increases the hydrostatic pressure in lymph vessels and causing it to leak in the peritoneum. Minoxidil must be considered as a probable cause of atraumatic drug induced chylous ascites.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Trial completion date, Trial initiation date, Trial primary completion date:  Effects of DPP4 Inhibition on COVID-19 (clinicaltrials.gov) -  Oct 7, 2020   
    P4,  N=20, Not yet recruiting, 
    These findings may indicate the beneficial effects of DPP-4 inhibitors on the progression of diabetic macrovascular complications. Trial completion date: Mar 2021 --> Dec 2021 | Initiation date: Oct 2020 --> Jan 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
  • ||||||||||  [VIRTUAL] Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients with Type 2 Diabetes in China () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1003;    
    OBJECTIVES : Agents that inhibit the dipeptidylpeptidase-4 (DPP-4) enzyme, including linagliptin, alogliptin, saxagliptin, sitagliptin and vildagliptin, become available for the treatment of Chinese patients with type 2 diabetes mellitus (T2DM)...Sensitivity analyses showed that the most influential parameters were the cost of DPP-4 inhibitors and their treatment efficacy. CONCLUSIONS : These results suggested that alogliptin was a preferred treatment option compared with other DPP-4 inhibitors for Chinese patients with T2DM inadequately controlled on metformin monotherapy.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Enrollment open, Trial initiation date:  Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 (clinicaltrials.gov) -  Oct 1, 2020   
    P3,  N=100, Recruiting, 
    Furthermore, there is a possibility that the amount of DPP-4-Is used clinically cannot increase the amount of substance P in sufficient quantity to prevent aspiration pneumonia. Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Oct 2020
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Trial completion:  Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses (clinicaltrials.gov) -  Sep 24, 2020   
    P=N/A,  N=48262, Completed, 
    Moreover, DPP-4i counteracted striatal age-related glial alterations suggesting striatal rejuvenation properties. Active, not recruiting --> Completed
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Onglyza (saxagliptin) / AstraZeneca
    Clinical, Journal:  Efficacy of Saxagliptin for Blood Glucose Control in Hemodialysis Patients with Diabetes (Pubmed Central) -  Sep 23, 2020   
    Lack of a substantial change in GA when the previous users of teneligliptin 20 mg and linagliptin 5 mg were switched to saxagliptin 2.5 mg indicates that these three agents might have comparable antihyperglycemic profiles when used in patients on hemodialysis. Future research following from this pilot study must evaluate the risk of cardiac failure and incidences of adverse events in a larger population, to investigate the long-term efficacy and safety of switching to saxagliptin.
  • ||||||||||  Review, Journal:  Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. (Pubmed Central) -  Sep 19, 2020   
    Despite some residual limitations linked to differences in study populations and patient characteristics, the cardiorenal protective actions of SGLT-2 inhibitors, and to a lesser extent by some GLP-1 agonists, make them favorable medications for patients with T2D at increased cardiorenal risk. There is room for optimism that their use may change the paradigm of the ineluctable progression of DKD.